A History of Helping Adults Across Seven Chronic Inflammatory Diseases

First approved by the FDA in 2008 for adults with moderately to severely active Crohn’s disease (not helped enough by usual treatments), CIMZIA was later approved to treat adults with moderately to severely active rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, moderate-to-severe plaque psoriasis (in adults who may benefit from taking injections or pills [systemic therapy] or phototherapy [treatment using ultraviolet light alone or with pills], active non-radiographic axial spondyloarthritis with measures of inflammation, and active polyarticular juvenile idiopathic arthritis.

CIMZIA was most recently FDA-approved in 2024 to treat active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.

*Includes studies related to FDA-approved indications of Crohn’s disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, non-radiographic axial spondyloarthritis, and polyarticular juvenile idiopathic arthritis, as well as additional ongoing and completed research.